Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...